NCT04233372View on ClinicalTrials.gov

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

PHASE4CompletedINTERVENTIONAL

Enrollment

399

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

July 28, 2022

Study Completion Date

July 28, 2022

Conditions

Hiv

Interventions

DRUG

Delstrigo

"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"

Trial Locations (2)

Unknown

Department and HIV & HCV Clinical Research Unit University Hospital Nantes, Nantes

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors

lead

Hospital Clinic of Barcelona

OTHER

NCT04233372 - Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study | Biotech Hunter | Biotech Hunter